As a result of hyperbilirubinemias, the daily dose of nilotinib for patients with UGT1A1*6/*6 or *6/*28 genotypes is approximately 300–400 mg/day, lower than for patients with UGT1A1 *1/*1, *1/*6, *1/*28, or *27/*28 genotypes (600 mg/day). The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.